BR0212742A - Composto opióide de diarilmetil-piperazina enantiomericamente puro e método de utilização do mesmo - Google Patents
Composto opióide de diarilmetil-piperazina enantiomericamente puro e método de utilização do mesmoInfo
- Publication number
- BR0212742A BR0212742A BR0212742-3A BR0212742A BR0212742A BR 0212742 A BR0212742 A BR 0212742A BR 0212742 A BR0212742 A BR 0212742A BR 0212742 A BR0212742 A BR 0212742A
- Authority
- BR
- Brazil
- Prior art keywords
- enantiomerically pure
- therapeutic agent
- compound
- utility
- opioid compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO OPIóIDE DE DIARILMETIL-PIPERAZINA ENANTIOMERICAMENTE PURO E MéTODO DE UTILIZAçãO DO MESMO". A presente invenção se refere a um composto de (-)3-(S)-((2S,5R)-4-alil-2,5-dimetil-1-piperazinil)-(3-tienil)-metil)fenol e ésteres ou sais farmaceuticamente aceitáveis do mesmo, em forma substancialmente e enantiomericamente pura, tendo utilidade como um tipo de ligante de receptor, por exemplo, como agente terapêutico para mediação de analgesia; como agentes co-administrados com diversas outras composições bioativas, incluindo anestésicos, barbituratos, analgésicos, etc., para redução, tratamento, reversão ou prevenção de depressão respiratória mediada por drogas, que pode ser direta ou indiretamente provocada pelo uso dessas diversas composições bioativas; como um conjugado em pares de agonista/antagonista para verificação/ensaio da função de receptor e neurotransmissor; e como um agente terapêutico que apresenta utilidade no combate ao vício de drogas, vício de álcool, distúrbios cardíacos, dose excessiva de drogas, doenças mentais, tosse, edema pulmonar, diarréia, distúrbios respiratórios e gastrintestinais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32471201P | 2001-09-25 | 2001-09-25 | |
PCT/US2002/030398 WO2003026660A1 (en) | 2001-09-25 | 2002-09-25 | An enantiomerically pure diarylmethylpiperazine and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212742A true BR0212742A (pt) | 2004-10-05 |
Family
ID=23264757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212742-3A BR0212742A (pt) | 2001-09-25 | 2002-09-25 | Composto opióide de diarilmetil-piperazina enantiomericamente puro e método de utilização do mesmo |
Country Status (16)
Country | Link |
---|---|
US (1) | US6924288B2 (pt) |
EP (1) | EP1438051A4 (pt) |
JP (1) | JP2005505575A (pt) |
KR (1) | KR20040041171A (pt) |
CN (1) | CN1558765B (pt) |
AU (1) | AU2002341832B2 (pt) |
BR (1) | BR0212742A (pt) |
CA (1) | CA2459577C (pt) |
IL (2) | IL160794A0 (pt) |
MX (1) | MXPA04002813A (pt) |
NO (1) | NO325958B1 (pt) |
NZ (1) | NZ531875A (pt) |
PL (1) | PL370346A1 (pt) |
RU (1) | RU2309153C2 (pt) |
WO (1) | WO2003026660A1 (pt) |
ZA (1) | ZA200402325B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189725B2 (en) * | 2001-09-25 | 2007-03-13 | Mount Cook Biosciences, Inc. | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent |
US7314880B2 (en) * | 2003-01-02 | 2008-01-01 | Mount Cook Biosciences, Inc. | Cardioprotective delta opioid receptor agonists and methods of using same |
US7683168B2 (en) * | 2005-04-14 | 2010-03-23 | Mount Cook Bio Sciences, Inc. | Compositions of novel opioid compounds and method of use thereof |
US20070197786A1 (en) * | 2005-07-22 | 2007-08-23 | Kwen-Jen Chang | Enantiomerically pure opioid diarylmethylpiperazine |
KR101319390B1 (ko) * | 2007-04-25 | 2013-10-17 | 엘지전자 주식회사 | 대중 교통 정보를 제공하고 이를 이용하는 방법 및 장치 |
CN105646332B (zh) * | 2014-11-09 | 2018-05-25 | 复旦大学 | 氨基甲基哌啶类衍生物及其制备方法和药物用途 |
US11246865B2 (en) | 2017-04-30 | 2022-02-15 | Versi Group, Llc | Opioid for use to reduce and/or treat drug addiction |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985880A (en) * | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5807858A (en) * | 1996-06-05 | 1998-09-15 | Delta Pharmaceutical, Inc. | Compositions and methods for reducing respiratory depression |
US20020052007A1 (en) | 1992-02-03 | 2002-05-02 | Chang Kwen Jen | Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives |
-
2002
- 2002-09-25 NZ NZ531875A patent/NZ531875A/en not_active IP Right Cessation
- 2002-09-25 RU RU2004107850/15A patent/RU2309153C2/ru not_active IP Right Cessation
- 2002-09-25 CA CA2459577A patent/CA2459577C/en not_active Expired - Fee Related
- 2002-09-25 JP JP2003530295A patent/JP2005505575A/ja active Pending
- 2002-09-25 MX MXPA04002813A patent/MXPA04002813A/es active IP Right Grant
- 2002-09-25 US US10/254,609 patent/US6924288B2/en not_active Expired - Lifetime
- 2002-09-25 EP EP02775985A patent/EP1438051A4/en not_active Withdrawn
- 2002-09-25 AU AU2002341832A patent/AU2002341832B2/en not_active Ceased
- 2002-09-25 IL IL16079402A patent/IL160794A0/xx unknown
- 2002-09-25 KR KR10-2004-7004162A patent/KR20040041171A/ko not_active Application Discontinuation
- 2002-09-25 WO PCT/US2002/030398 patent/WO2003026660A1/en active Application Filing
- 2002-09-25 PL PL02370346A patent/PL370346A1/xx unknown
- 2002-09-25 BR BR0212742-3A patent/BR0212742A/pt not_active IP Right Cessation
- 2002-09-25 CN CN028187806A patent/CN1558765B/zh not_active Expired - Fee Related
-
2004
- 2004-03-09 IL IL160794A patent/IL160794A/en not_active IP Right Cessation
- 2004-03-24 ZA ZA200402325A patent/ZA200402325B/en unknown
- 2004-04-23 NO NO20041729A patent/NO325958B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2003026660A1 (en) | 2003-04-03 |
US20030114462A1 (en) | 2003-06-19 |
EP1438051A1 (en) | 2004-07-21 |
US6924288B2 (en) | 2005-08-02 |
CN1558765A (zh) | 2004-12-29 |
NO325958B1 (no) | 2008-08-25 |
JP2005505575A (ja) | 2005-02-24 |
IL160794A (en) | 2012-08-30 |
CN1558765B (zh) | 2012-01-04 |
CA2459577A1 (en) | 2003-04-03 |
NZ531875A (en) | 2006-10-27 |
MXPA04002813A (es) | 2005-06-06 |
NO20041729L (no) | 2004-06-25 |
IL160794A0 (en) | 2004-08-31 |
KR20040041171A (ko) | 2004-05-14 |
RU2004107850A (ru) | 2005-04-20 |
AU2002341832B2 (en) | 2008-10-30 |
CA2459577C (en) | 2012-01-24 |
EP1438051A4 (en) | 2005-01-05 |
PL370346A1 (en) | 2005-05-16 |
ZA200402325B (en) | 2005-01-13 |
RU2309153C2 (ru) | 2007-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Menigaux et al. | Intraoperative small-dose ketamine enhances analgesia after outpatient knee arthroscopy | |
BR0003365A (pt) | Composições farmacêuticas | |
WO2007126362A8 (en) | Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia | |
RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
BRPI0513300A (pt) | forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol | |
BR0212019A (pt) | Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem | |
BRPI0417771A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóides | |
LT2001119A (en) | Pharmaceutical formulations comprising intranasal morphine and use thereof | |
WO2001076575A3 (en) | The treatment of respiratory diseases | |
WO2003045437A8 (en) | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene | |
BR0011894A (pt) | Forma de dosagem oral, processo para a fabricação de forma de dosagem, uso de forma de dosagem farmacêutica oral, e, métodos para aumentar inibição de secreção do ácido gástrico e para aumentar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com excesso de secreção ácida | |
NO996310L (no) | Sammensetninger og fremgangsmÕter for Õ redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser | |
BR0116605A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono | |
BRPI0511224A (pt) | método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente | |
WO2007009806A3 (en) | Solid dosage formulations of narcotic drugs having improved buccal adsorption | |
WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
UA96302C2 (en) | Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid | |
BR0212929A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade | |
Elhakim et al. | Ketamine reduces swallowing‐evoked pain after paediatric tonsillectomy | |
JP2009522376A5 (pt) | ||
BR0112661A (pt) | Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica | |
BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
BR0208111A (pt) | Composto, utilização de um composto, processo de tratamento de distúrbios, processo para preparação de composto, composição farmacêutica que compreende o composto e processo de tratamento de obesidade | |
BR0212742A (pt) | Composto opióide de diarilmetil-piperazina enantiomericamente puro e método de utilização do mesmo | |
WO2006053012A3 (en) | Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: MOUNT COOK BIOSCIENCES, INC. (US) Free format text: TRANSFERIDO DE: ARDENT PHARMACEUTICALS, INC. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUI DADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |